InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies ...

Bruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and relapsed ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...

Taiwanese streamer Catchplay and production outfit Screenworks Asia are making a big push into microdrama in partnership with ...

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted ...

Communication gaps persisted despite shared decision-making norms, with limited patient-perceived comprehension and ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...